Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
397.7 USD | -0.76% | +1.07% | -2.26% |
12:26pm | Wolfe Research Adjusts Price Target on Vertex Pharmaceuticals to $497 From $515 | MT |
Apr. 23 | Vertex Pharmaceuticals in T1D Licensing Pact With TreeFrog Therapeutics | DJ |
Summary
- The company has strong fundamentals. More than 70% of companies have a lower mix of growth, profitability, debt and visibility.
Strengths
- Before interest, taxes, depreciation and amortization, the company's margins are particularly high.
- Margins returned by the company are among the highest on the stock exchange list. Its core activity clears big profits.
- Thanks to a sound financial situation, the firm has significant leeway for investment.
- Analysts have consistently raised their revenue expectations for the company, which provides good prospects for the current and next years in terms of revenue growth.
- Over the past four months, analysts' average price target has been revised upwards significantly.
- Historically, the company has been releasing figures that are above expectations.
Weaknesses
- With a 2024 P/E ratio at 26.9 times the estimated earnings, the company operates at rather significant levels of earnings multiples.
- Based on current prices, the company has particularly high valuation levels.
- In relation to the value of its tangible assets, the company's valuation appears relatively high.
- The overall consensus opinion of analysts has deteriorated sharply over the past four months.
- Over the past twelve months, analysts' opinions have been revised negatively.
Ratings chart - Surperformance
Chart ESG Refinitiv
Sector: Biotechnology & Medical Research
1st Jan change | Capi. | Investor Rating | ESG Refinitiv | |
---|---|---|---|---|
-3.21% | 104B | B+ | ||
+0.89% | 97.42B | B+ | ||
+0.79% | 22.2B | B | ||
-17.97% | 21.23B | B+ | ||
-11.11% | 18.33B | A- | ||
-42.83% | 16.35B | A- | ||
-16.66% | 15.06B | B | ||
+3.81% | 13.98B | C+ | ||
+31.47% | 11.66B | C+ | ||
-25.88% | 8.22B | D |
Financials
Valuation
Momentum
Consensus
Business Predictability
Environment
Governance
Controversy
Technical analysis
- Stock Market
- Equities
- VRTX Stock
- Ratings Vertex Pharmaceuticals Incorporated